We are excited to announce that we have started construction of a state-of-the-art integrated biologics solution center at our headquarters in Shanghai.  WuXi plans to invest a total of $120 million in this dedicated, 250,000-square-foot facility, which will accommodate 800 scientists.  The facility will provide integrated solutions from ideas to the clinic for biologics discovery, development, and clinical manufacturing on a consolidated campus. With a comprehensive platform integrated from discovery through all aspects of development, customers will benefit from the speed, agility, efficiency, and unsurpassed quality of WuXi’s operations to expedite their global biologics research and development.  The facility is expected to be fully operational by 2017.  We are very pleased to continue to invest in our biologics capabilities and expand our capacities to support the ambitious plans of our global clients.


Related Links:

  1. WuXi and MedImmune Form a Strategic Alliance to Develop Innovative Biologics in China for AstraZeneca
  2. WuXi Biologics Begins Construction of the World’s Largest Mammalian Cell Culture Manufacturing Facility Using Disposable Bioreactors